Rosy  Wills

Rosy Wills

Followers 0
Following 0
According to a new market research report Biopsy Devices Market by Product (Core Needle Biopsy, Aspiration Biopsy, Vacuum Assisted Biopsy) Application (Breast Biopsy, Lung Biopsy, Prostate Biopsy) Guidance (Stereotactic, Ultrasound) & by End User (Hospital) - Global Forecast to 2022, published by MarketsandMarkets™, the market is expected to reach USD 2.42 Billion by 2022 from an estimated USD 1.74 Billion in 2017, at a CAGR of 6.8% during the forecast period.Browse 180 Market Data Tables and 42 Figures spread through 219 Pages and in-depth TOC on "Biopsy Devices Market"Download PDF Brochure: http://www.marketsandmarkets.com/pdfdownload.asp?id=132886515 The Report analyzes and studies the major market drivers, restraints, and opportunities in North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa.Factors such as rising prevalence of cancer, increasing preference for minimally invasive surgeries, and initiatives undertaken by governments & global health organizations are the major factors driving the growth of this market.By product, the needle-based biopsy instruments segment accounted for the largest share of the marketOn the basis of product, the needle-based biopsy instruments segment accounted for the largest share of the global biopsy devices market in 2016.This can be attributed to the preference of needle-based biopsies over open surgical biopsies and increasing preference for minimally invasive surgeries.The lung biopsy segment is expected to highest growth during the forecast periodBased on application, the lung biopsy segment accounted for the largest share of the biopsy devices market.Additionally, the availability of funding for lung cancer research is contributing to the growth of this market segment.The ultrasound-guided biopsy segment dominated the market in 2016Based on guidance technique, the ultrasound-guided biopsy segment accounted for the largest share of the biopsy devices market.This quick and simple procedure offers advantages, such as no ionizing radiation exposure, low complication rate, and lower cost as compared to other biopsy techniques.The hospitals segment held the highest CAGR during the forecast periodBased on end user, the hospitals segment is expected to register the highest growth rate during the forecast period.The strong financial capabilities of hospitals and the presence of trained professionals are the major factors supporting the rising adoption of biopsy devices among hospitals.North America dominated the market in 2016North America accounted for the largest share of the biopsy devices market in 2016, followed by Europe.The rising prevalence of cancer, government initiatives to spread awareness about cancer, favorable reimbursement scenario for biopsy devices in the U.S., and the presence of key players in the region are the key factors driving the growth of the biopsy devices market in North America.Request For Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=132886515 The major players in the biopsy devices market are C. R. Bard, Inc. (U.S.), Becton, Dickinson and Company (U.S.), Cook Group Incorporated (U.S.), Devicor Medical Products, Inc., (Leica Biosystems) (Germany), Argon Medical Devices (U.S.), B. Braun Melsungen AG (Germany), Cardinal Health, Inc. (U.S.), Olympus Corporation (Japan), Boston Scientific Corporation (U.S.), FUJIFILM Holdings Corporation (Japan), INRAD, Inc. (U.S.), and Medtronic plc (Ireland).About MarketsandMarkets™MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues.
According to the new market research report Medical Device Contract Manufacturing Market by Device Type (IVD (Equipment, Consumable), Cardiovascular, Diabetes Care, Drug Delivery, Orthopedic, Ophthalmic, Endoscopy Devices), Class of Device (Class I, II, III), & Services - Global Forecast to 2026, published by MarketsandMarkets™, the global market is estimated to reach USD 113.3 billion in 2026 from USD 65.9 billion in 2021, at a CAGR of 11.5% during the forecast period.Browse in-depth TOC on “Medical Device Contract Manufacturing Market”292 – Tables59 – Figures361 – PagesDownload PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=170622851 The key factors driving the growth of the medical device contract manufacturing market include the overall growth of the medical devices market, mainly due to rising disease prevalence, life expectancy, and the geriatric population.In addition to this, the COVID-19 outbreak has accelerated the adoption of advanced diagnostics and patient care devices for better treatment management.However, market growth is impeded by the growing consolidation in the medical devices market.Larger players, to develop their manufacturing capabilities to save costs, focus on the acquisition of smaller players and CMOs themselves.This may affect the overall pace of market growth.The IVD devices segment accounted for the largest share of medical device contract manufacturing market in 2020Based on device type, the market is broadly segmented into IVD devices, diagnostic imaging devices, cardiovascular devices, drug delivery devices, orthopedic devices, respiratory care devices, ophthalmology devices, surgical devices, diabetes care devices, dental devices, endoscopy devices, gynecology/urology devices, personal care devices, neurology devices, and other devices.In addition, due to the outbreak of COVID-19, governments minimized the regulatory compliance on these devices and issued Emergency Use Authorizations (EUA) for diagnostics and PPE kits, thereby boosting the market growth.In 2020, the device development and manufacturing services segment accounted for the largest share of the marketBased on service, the medical device contract manufacturing market is segmented into device development and manufacturing services, quality management services, packaging and assembly services and other services.The dominant share of the APAC region is mainly attributed to the lower cost of raw materials & labor compared to the developed countries, the increasing demand for medical devices due to improving healthcare infrastructure, the adoption of technologically advanced products, and the presence of a less stringent regulatory than most developed countries.Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=170622851 The prominent players in this market are Flex, Ltd. (Singapore), Jabil, Inc. (US), TE Connectivity, Ltd. (Switzerland), Sanmina Corporation (US), Nipro Corporation (Japan), Celestica International (Canada), Plexus Corporation (US), Benchmark Electronics, Inc. (US), Integer Holdings Corporation (US), Gerresheimer Ag (Germany), West Pharmaceutical Services, Inc. (US), Nortech Systems, Inc. (US), Consort Medical PLC (UK), Kimball Electronics Inc. (US), and Teleflex Incorporated (US), Tecomet, Inc. (US), SMC Ltd. (US), Nemera (France), and Tessy Plastics Corporation (US), among others.About MarketsandMarkets™MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues.
According to the new market research report Contrast Media Market by Type (Iodinated Contrast Media), Modality (X-Ray/CT, MRI, and Ultrasound), Application (Radiology), End User (Hospitals), Indication (Cancer), Route of Administration (Oral), Region - Global Forecast to 2026, published by MarketsandMarkets™, the global Contrast Media Market is projected to USD 5.9 billion by 2026 from USD 4.9 billion in 2021, at a CAGR of 3.7% during the forecast period.Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=911 The Rising prevalence of chronic diseases, growing approvals of contrast agents, rising volume of CT and MRI examinations performed, growing number of diagnostic centers and hospitals, and availability of reimbursement are the major factors driving the growth of the contrast agents market.The microbubble contrast media segment is expected to grow at the highest CAGR during the forecast period and iodinated contrast media accounted for the largest share in 2020.Based on type, the contrast media market is segmented into iodinated contrast media, gadolinium-based contrast media, microbubble contrast media, and barum-based contrast media.The large share of this segment can be attributed to the growing number of angioplasty procedures performed globally.North America was the largest regional market for the contrast agents market in 2020The contrast media market is segmented into five major regions, namely, North America, Europe, Asia Pacific, Latin America and the Middle East & Africa (MEA).The large share of the North American market can be attributed to presence of major players in the region, high prevalence of chronic disorders, growing geriatric population, and the increasing adoption of minimally invasive procedures.However, the Asia Pacific contrast media market is estimated to grow at the highest CAGR during the forecast period.The rising prevalence of chronic diseases, the growing demand for quality medical care, increasing healthcare spending and government initiatives, rising disposable income, growth in the medical device industries, and improvements in healthcare infrastructure in Southeast Asian countries are the major factors driving the growth of the market in the Asia Pacific.Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=911 The global contrast media market is consolidated.Chemicals and Pharmaceuticals Ltd. (India), Lantheus Medical Imaging, Inc. (US), Unijules Life Sciences Ltd. (India), and SANOCHEMIA Pharmazeutika GmbH (Austria).About MarketsandMarkets™MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues.Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients.
According to the new market research report "Defibrillators Market by Product [Implantable Cardioverter Defibrillator (Transvenous ICD, Single & Dual Chamber, CRT-D, S-ICD), External (Manual, AED, Wearable)], End User (Hospitals, Pre-hospital, Public Access, Home care) - Global Forecast to 2025", published by MarketsandMarkets™, the Defibrillators Market is projected to reach USD 11.7 billion by 2025 from USD 9.6 billion in 2019, growing at a CAGR of 3.4% during the forecast period.Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=549 The growth in this market is driven by the rising prevalence of target diseases, growing focus on providing public-access defibrillators, and training and awareness programs on defibrillators.In addition, emerging markets and the development of S-ICDs and MRI-compatible ICDs and CRT-Ds are expected to offer growth opportunities for players in the market.However, issues related to the use of implantable and automated external defibrillators, frequent product recalls, and a lack of awareness about sudden cardiac arrest in developing nations are expected to hinder the growth of the market during the forecast period.Browse in-depth TOC on "Defibrillators Market"132 – Tables30 – Figures158 – PagesThe ICDs segment accounted for the largest share of the market in 2019On the basis of type, the market is segmented into implantable cardioverter defibrillators (ICDs) and external defibrillators.The ICDs market is further segmented into transvenous implantable cardioverter defibrillators (T-ICDs) and subcutaneous implantable cardioverter defibrillators (S-ICDs).Factors such as the development of technologically advanced devices with extended longevity, rapid growth in the number of implant procedures, and increasing adoption of cardiac resynchronization therapy defibrillators (CRT-Ds) and S-ICD systems across the globe are contributing to the large share of this segment.The hospitals, clinics, and cardiac centers segment accounted for the largest share of the global Defibrillators Market in 2019On the basis of end users, the market is segmented into hospitals, clinics, and cardiac centers; prehospital care settings; public access markets; alternate care facilities; and home care settings.The growing number of cardiac implant procedures and the availability of reimbursements across developed markets are the major factors driving the growth of this end-user segment.In 2019, North America accounted for the largest share of the Defibrillators MarketIn 2019, North America accounted for the largest share of the market.
According to the new market research report “Oral Care Market by Product (Toothbrush (Manual, Electric, Battery), Toothpaste (Pastes, Gels, Powder, Polish), Breath Freshener, Rinse & Distribution Channel (Consumer Stores, Retail Pharmacy, E-Commerce), and Region- Global Forecast to 2025”, published by MarketsandMarkets™, the Oral Care Market is projected to reach USD 53.3 billion by 2025 from USD 45.8 billion in 2020, at a CAGR of 3.1%.Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=80546246 The Factors such as the rising awareness about oral hygiene, growing incidence of dental diseases, and technological advancements in oral care products are expected to drive the growth of the Oral Care Market.The large share of this segment can primarily be attributed to the enormous adoption of toothpaste for maintaining oral hygiene, the treatment of dental caries, and its use in post-surgical procedures.Browse in-depth TOC on “Oral Hygiene Market”367 – Tables47 – Figures336 – PagesBy distribution channel, the online distribution segment is expected to grow at the fastest CAGR in the forecast periodBy distribution channel, the Oral Hygiene Market is segmented into consumer stores, retail pharmacies, dental dispensaries, and online distribution.This high growth can be attributed to the increase in the number of e-commerce platforms focused on oral care/oral hygiene products, better convenience and availability of a variety of products through this channel along with proper discounts.The Asia Pacific is expected to dominate the market in 2019 as well as serves higher growth potential during the forecast period.In 2019, the Asia Pacific was estimated to account for the largest share of the Oral Care Market, followed by Europe.The dominant share of the Asia Pacific is attributed mainly to the rising geriatric population, growing prevalence of dental diseases, increasing focus of prominent players on emerging Asian countries, increasing healthcare expenditure (coupled with the increasing disposable income), raising awareness on oral healthcare, and the willingness to spend more on dental care.Other factors, such as the growing number of dental professionals, along with the increasing number of dental visits, will further support the growth of the Oral Hygiene Market in this regional segment during the forecast period.Request For Report Sample: https://www.marketsandmarkets.com/requestsampleNew.asp?id=80546246 The key players operating in the Oral Care Product Market include Colgate-Palmolive Company (US), The Procter & Gamble Company (US), GlaxoSmithKline PLC (UK), Unilever PLC (UK), Koninklijke Philips N.V. (Netherlands), Johnson & Johnson (US), GC Corporation (Japan), 3M Company (US), Lion Corporation (Japan), Church & Dwight Co., Inc. (US), Sunstar Suisse S.A. (Switzerland).About MarketsandMarkets™MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues.Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients.
According to a new market research report "EMO Machine Market by Modality (Veno-Arterial (VA), Veno-Venous (VV), Arterio-Venous (AV)), Application (Respiratory, Cardiac, Extracorporeal Cardiopulmonary Resuscitation (ECPR)), and Region - Analysis & Forecasts to 2021" published by MarketsandMarkets, The market is expected to reach USD 305.3 Million by 2021 from USD 247.2 Million in 2016, at a CAGR of 4.3%.Browse 78 market data Tables and 31 Figures spread through 129 Pages and in-depth TOC on "Extracorporeal Membrane Oxygenation Machine Market"Download PDF Brochure: http://www.marketsandmarkets.com/pdfdownload.asp?id=255167654 The report analyzes and studies the major market drivers, restraints/challenges, and opportunities for the forecast period of 2016 to 2021.However, complications associated with ECMO such as bleeding, infections, and technical failures; along with high cost and lack of skilled professionals is a challenge to the market.The global ECMO machine market is segmented on the basis of modality, applications, and regions.The large share of this segment can be attributed to factors such as rising incidence of respiratory failure, lung cancer, and lung transplants, and increasing adoption of ECMO.On the basis of region, the global ECMO machine market is divided into North America, Europe, Asia-Pacific, and the Rest of the World (RoW).In 2016, North America accounted for the largest share of the market, followed by Europe, Asia-Pacific, and the Rest of the World.The Asia-Pacific market is projected to grow at the highest CAGR and serve as a revenue pocket for companies offering ECMO systems.Request For Sample Pages: http://www.marketsandmarkets.com/requestsample.asp?id=255167654 In 2015, the market was dominated by the Getinge Group (Sweden), Medtronic plc (Ireland), and LivaNova PLC (U.K.).The other players in the Extracorporeal Membrane Oxygenation Machine Market are XENIOS AG (Germany), Terumo Corporation (Japan), MicroPort Scientific Corporation (China), NIPRO Corporation (Japan), OriGen Biomedical, Inc. (U.S.), ALung Technologies, Inc. (Germany), and EUROSETS S.r.l.
According to the new market research report "Life Science Analytics Market by Type (Predictive, Descriptive, Prescriptive), Application (Marketing, Compliance, Clinical trial, R, Pharmacovigilance, SCM), Component (Software, Service), Delivery, End User, & Region - Global Forecast To 2025", published by MarketsandMarkets™, the global Life Science Analytics Market size is expected to reach 42.0 billion by 2025 from USD 22.1 billion in 2020, at a CAGR of 13.7% during the forecast period of 2020 to 2025.Browse and in-depth TOC on "Life Science Analytics Market"426- Tables41- Figures301- PagesDownload PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=174990653 The Growth in this Pharmaceutical Analytics Software Market is mainly driven by technological advancements, big data in the life science industry, growing adoption of analytics solutions in clinical trials, increasing adoption of analytics for sales and marketing applications, need for improved data standardization, increasing prevalence of chronic diseases, growing pressure to curb healthcare spending, and the need for improved patient outcomes.On the other hand, high implementation costs are expected to restrain the growth of this market to a certain extent.The on-demand model segment is expected to grow at the highest CAGR during the forecast period.Based on the delivery mode, the Life Science Analytics Market is segmented into the on-demand model and the on-premise model.The on-demand model segment is expected to grow at the highest CAGR during the forecast period, owing to advantages such as increasing demand for self-driven analytics, lack of upfront capital investments for hardware, extreme capacity flexibility, and pay-as-you-go pricing of this model.The descriptive analytics segment accounted for the largest market share in 2019.Based on type, the market is segmented into descriptive analytics, predictive analytics, and prescriptive analytics.The descriptive analytics segment accounted for the largest share of the Pharmaceutical Analytics Software Market in 2019.Growth in the North American market is supported by the growing adoption of IT in the life science industry, rising pressure to reduce healthcare costs, stringent regulations for the pharma-biotech and medical device industries, and the greater product and service availability in this region.Request For Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=174990653 The prominent players operating in the Life Science Analytics Market are Oracle Corporation (US), Accenture (Ireland), SAS Institute Inc. (US), IBM Corporation (US), Wipro (India), Cognizant (US), SCIO Health Analytics (US), Allscripts Healthcare Solutions (US), Cerner Corporation (US), IQVIA (US), Microsoft (US), Infosys Limited (US), MaxisIT (US), Optum (US), and Cotiviti (US).About MarketsandMarkets™MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies' revenues.Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients.
According to the new market research report “Remote Patient Monitoring Market by Product (Software, Services, Devices, Cardiology, Neurological, Blood Glucose, Neonatal, Weight, Temperature, Neuro) End User (Providers, Hospitals, Clinics, Home Care, Patients, Payers) – Global Forecast to 2025″, published by MarketsandMarkets™, the global RPM Market size is projected to reach USD 117.1 billion by 2025 from USD 23.2 billion in 2020, at a CAGR of 38.2% between 2020 and 2025.Browse in-depth TOC on “Remote Patient Monitoring Market”149 – Tables34 – Figures189 – PagesDownload PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=77155492 The rising geriatric population and the growing need to expand healthcare access, cost benefits of telehealth and remote patient monitoring, benefits of RPM to reduce the burden on medical resources, advancements in telecommunications, growing incidences of chronic diseases, and increasing investments in telehealth and RPM are the major factors driving the growth of this market.However, the regulatory variations across regions, healthcare fraud, and informal usage of social media practices is expected to restrain the market growth during the forecast period.Software and services to dominate the remote patient monitoring market in 2019Based on the product, the RPM Market is segmented into software & services and devices.The large share of this segment is mainly due to the increasing reimbursement for RPM programs and the rising number of chronic illnesses, thus leading to the growing adoption of RPM services across the globe.Providers segment accounted for the largest share of the remote patient monitoring market, by end user, in 2019Based on end users, the global market is broadly segmented into providers, payers, patients, and other end users.This can be attributed to the increased adoption of remote monitoring in chronically ill and old aged patients, advancements in RPM monitoring devices, and the increasing number of RPM services offered by providers.North America is the largest regional market for remote patient monitoring in 2019In 2019, North America accounted for the largest share of the remote patient monitoring market, followed by Europe.The large share of North America in the RPM Market can be attributed to the rising prevalence of chronic conditions, the need to reduce healthcare expenditure, and the increasing overall & geriatric population.Request For Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=77155492 Prominent players in the remote patient monitoring market are BioTelemetry Inc. (US), Koninklijke Philips N.V. (Netherlands), Medtronic (Ireland), GE Healthcare (US), Cerner Corporation (US), Siemens Healthineers AG Germany, OMRON Healthcare (Japan), Boston Scientific Corporation (US), Abbott Laboratories (US), Resideo Life Care Solutions (US), Vivify Health, Inc. (US), ALTEN Calsoft Labs (France), Preventice Solutions (US), Bio-Beat Technologies (Israel), VitalConnect (US), Welch Allyn (US), Teladoc Health Inc. (US), Dexcom Inc. (US), iRhythm Technologies, Inc. (US), and VivaLNK Inc. (US).About MarketsandMarkets™MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues.Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients.
According to research report the Cancer Biomarkers Market was valued at USD 11.5 billion in 2017 and is estimated to grow at a CAGR of 12.2% during the forecast period, to reach USD 20.4 billion by 2022.The increasing prevalence of cancer, rising government support for research on cancer biomarkers, growing use of biomarkers in drug discovery and development, and increasing use of biomarker tests for diagnostic purposes are the major factors that are driving the growth of this market.Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=202 Browse 268 market data Tables and 37 Figures spread through 249 Pages and in-depth TOC on "Cancer Biomarkers Market by Type (Protein Biomarker, Genetic Biomarker), Cancer Type (Breast, Melanoma, Leukemia, Lung), Profiling Technology (Omics, Imaging, Immunoassay, Bioinformatics), Application (Diagnosis, Prognostics, R) - Global Forecast to 2022"The breast cancer segment accounted for the largest share of the cancer biomarkers market in 2016Based on cancer type, the cancer biomarkers market is segmented into breast, lung, colorectal, prostate, melanoma, leukemia, thyroid, bladder, non-Hodgkins lymphoma, kidney, and other cancers (such as cervical, multiple myeloma, CNS, gastric, liver, pancreatic, oral cavity and pharynx, stomach, and ovarian cancers).The breast cancer segment accounted for the largest share of this market owing to the high and growing prevalence of breast cancer, increasing awareness about breast cancer, rising number of breast cancer screening programs, and growing research on breast cancer.The genetic biomarkers segment is expected to grow at the highest CAGR during the forecast periodBased on biomarker type, the cancer biomarkers market is segmented into genetic biomarkers, protein biomarkers, and other biomarkers (cell, viral, and carbohydrate biomarkers).During the forecast period, the genetic biomarkers segment is estimated to grow at the highest CAGR majorly due to advancements in high-throughput technologies, such as next-generation sequencing, which have enhanced the speed and accuracy of genetic biomarker discovery and diagnosis.North America was the largest regional market for cancer biomarkers in 2016North America accounted for the largest share of the cancer biomarkers market in 2017, followed by Europe.North America is the largest market for cancer biomarkers majorly due to government support (in the US and Canada) for the discovery and development of biomarkers, rising use of biomarkers in drug discovery and development by pharmaceutical companies, adoption of advanced omics technologies for biomarker discovery, and the increasing demand for personalized medicine in the region.Request For Report Sample: https://www.marketsandmarkets.com/requestsampleNew.asp?id=202 The major players operating in the cancer biomarkers market are Abbott (US), Affymetrix (US), Roche (Switzerland), Illumina (US), QIAGEN (Netherlands), Agilent (US), Thermo Fisher (US), Merck (US), Becton Dickinson and Company (US), and Hologic (US).About MarketsandMarkets™MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies' revenues.Currently servicing 5000 customers worldwide including 80% of global Fortune 1000 companies as clients.
According to the new market research report “Diagnostic Electrocardiograph Market By Product (Resting ECG, Stress, Mobile Cardiac Telemetry Device, Implantable Loop Recorder) and Service, By Lead Type (12-lead, 6-lead, 5- lead), End User, and Region – Global Forecast to 2024″, published by MarketsandMarkets™, the global Diagnostic Electrocardiograph Market is expected to reach USD 10.3 billion by 2024 from USD 7.5 billion in 2019, at a CAGR of 6.4% during the forecast period.Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=173 The Factors such as the rising incidence of lifestyle & cardiovascular diseases and increasing geriatric population are expected to propel the growth of the market.The hospitals, clinics, and cardiac centers segment accounted for the largest share of the Diagnostic Electrocardiograph (ECG) Market in 2018By end user, the market is classified into hospitals, clinics, and cardiac centers; ambulatory surgical centers; and other end users.In 2018, the hospitals, clinics, and cardiac centers segment accounted for the largest share of the market.The large share of this segment can primarily be attributed to the growing burden of cardiovascular diseases, which, in turn, is increasing the need for quality cardiology care.Browse in-depth TOC on “Diagnostic Electrocardiograph (ECG) Market”127 – Tables27 – Figures142 – PagesThe 3-lead ECG segment is expected to grow at the highest CAGR in the diagnostic ECG market during the forecast periodBy lead type, the diagnostic ECG market is divided into 12-lead, 5-lead, 3-lead, 6-lead, single-lead, and other lead types (15- and 18-lead).This positive growth is primarily due to the fact that these leads are used conjointly with various other cardiac diagnostic tests and during medical procedures.Asia Pacific diagnostic ECG market is expected to grow at the highest CAGR during the forecast periodOn the basis of region, the diagnostic ECG market is segmented into North America, Europe, Asia Pacific, and RoW.Factors such as growth in the geriatric population, growing incidence of chronic diseases, rising healthcare spending, healthcare reforms for infrastructural development, growing demand for advanced technologies, and less stringent regulations are fueling the demand for diagnostic ECG products and services in this region.Request For Report Sample: https://www.marketsandmarkets.com/requestsampleNew.asp?id=173 Market Players:The Diagnostic Electrocardiograph (ECG) Market is dominated by players such as GE Healthcare (US), Philips Healthcare (Netherlands), Nihon Kohden (Japan), Hill-Rom Holdings (US), and Ambu (Denmark).About MarketsandMarkets™MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues.Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients.
According to the new market research report Cardiac Monitoring Market is projected to reach USD 26.8 billion by 2025 from USD 22.1 billion in 2020, at a CAGR of 4.0% from 2020 to 2025.Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=55The growth of this market is driven by the increasing prevalence of cardiovascular diseases; availability of reimbursement for CM & CRM devices; launch of innovative products by market players; increasing investments, funds, and grants for research on CM & CRM devices; and the growing preference for wearable cardiac devices.On the basis of cardiac rhythm management devices by type, the market is segmented into defibrillators and pacemakers.In 2019, the defibrillators segment accounted for the largest market share.Factors such as technological advancements in defibrillators, rising prevalence of CVD, and growing focus on providing public-access defibrillators are driving the growth of this market.By end user, the cardiac rhythm management devices market is segmented into hospitals; clinics, cardiac centers, and ambulatory surgery centers (ASCs); and other end users.The large share of this segment can be attributed to factors such as the increasing prevalence of CVD, the growing number of patient visits to hospitals for diagnosis, increasing number of cardiac implant procedures, and the availability of reimbursement for these procedures across developed marketsOn the basis of cardiac monitoring devices by type, the market is segmented into ECG devices, event monitors, implantable loop recorders (ILRs), cardiac output monitoring (COM) devices, mobile cardiac telemetry (MCT) devices, and smart ECG monitors.The large share of this segment can be attributed to technological advancements such as the incorporation of advanced algorithms and workflow improvement features, such as simplified operations, touchscreen systems, portability, wireless features, and better connectivity with cardiovascular information systems (CVIS), electronic medical records (EMRs), and ECG management systems.On the basis of region, the cardiac monitoring & cardiac rhythm management devices market is segmented into North America, Europe, Asia Pacific, and Rest of the World.In 2019, North America commanded the largest share of the cardiac monitoring & cardiac rhythm management devices market.
According to the new market research report "Stable Isotope Labeled Compounds Market by Type (Carbon 13, D, Oxygen 18, N15), Application (Research, Clinical Diagnostics, Industrial), End User (Pharmaceutical & Biopharmaceutical Companies, Academic institute), Region – Global Forecast to 2024", published by MarketsandMarkets™, the Stable Isotope Labeled Compounds Market is projected to grow at a CAGR of 3.0% during the forecast period to reach USD 312 million by 2024 from USD 269 million in 2019.Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=53034199 The Factors such as the increase in research activities in the pharmaceutical and biotechnology sector, rising proteomics research, and the rising prevalence of cancer.The H-2 labeled compounds segment accounted for the largest share of the Stable Isotope Labeled Compounds Market.Based on type, the stable isotope labeled compounds industry is segmented into C-13, N-15, O-18, H-2 (deuterium), and other isotopes.The large share of this segment can be attributed to the increasing pharmaceutical research conducted using deuterium and the growing nuclear industry.This growth in this segment is driven primarily by increasing drug research in the pharmaceutical industry and the rising availability of deuterium-labeled compounds.Browse in-depth TOC on "Stable Isotope Labeled Compounds Market"118 – Tables21 – Figures135 – PagesThe research segment accounted for the largest share of the Stable Isotope Labeled Compounds Market in 2019.Based on application, the Stable Isotope Labeled Compound Market is segmented into research, clinical diagnostics, industrial applications, and other applications.The research segment accounted for the largest share of the stable isotope-labeled compounds market in 2019, owing to rising research activities in the biomedical, pharmaceutical, environmental & ecological, and agricultural sectors.North America to dominate the stable isotope labeled compounds systems industry during the forecast periodIn 2019, North America dominated the Stable Isotope Labeled Compounds Market, followed by Europe.The major factors driving the growth of this market include the growth of the pharmaceutical and biopharmaceutical industry, the large nuclear industry in the US, the growth of the Canadian pharmaceutical industry, and the availability of funding in North American countries.Request For Report Sample: https://www.marketsandmarkets.com/requestsampleNew.asp?id=53034199 The prominent players in this market include PerkinElmer Inc. (US), Merck KGaA (Germany), Cambridge Isotope Laboratories, Inc. (US), URENCO Limited (UK), IsoSciences, LLC (US), Medical Isotopes, Inc. (US), Omicron Biochemicals, Inc. (US), Trace Sciences International (US), Alsachim (France), Taiyo Nippon Sanso Corporation (Japan), and Rotem Industries Israel Ltd. (Israel).About MarketsandMarkets™MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies' revenues.Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients.
According to the new market research report Dental Equipments Market is estimated to reach USD 6.2 billion in 2021 and is projected to reach USD 8.9 billion by 2026, at a CAGR of 7.7% during the forecast period.Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=784The dental equipment market is estimated to witness significant growth during the forecast period due to the increasing prevalence of oral health disorders, sedentary and changing lifestyles, growing consumer awareness, and rising dental tourism.An increasing number of dental laboratories investing in CAD/CAM technologies will provide abundant opportunities.However, the high cost of dental imaging systems and lack of reimbursement for dental procedures are expected to restrain the growth of this market during the forecast period.The prominent players in the dental equipment industry are DENTSPLY Sirona (US), Planmeca Group (Finland), Envista Holdings (US), Align Technology (US), A-dec Inc. (US), J. MORITA CORP. (Japan), GC Corporation (Japan), Midmark Corporation (US), Straumann Holdings AG (Switzerland), 3M Company (US), BIOLASE, Inc. (US), 3Shape A/S (Denmark), BEGO GmbH & Co. Kg (Germany), Ultradent Products, Inc. (US), Yoshida Dental MFG.Co., Ltd. (Japan), Nakanishi Inc. (Japan), DentalEZ, Inc. (US), Carestream Dental LLC.(US), Takara Belmont Corporation (Japan), Nova Instruments (UK), NewTom (Italy), Millennium Dental Technologies, Inc. (US), PreXion, Inc. (Japan), Brasseler USA (US), Ivoclar Vivadent AG (Liechtenstein), AMD LASERS (US), Aseptico (US), and BIEN-AIR DENTAL (US), among others.R is another important consideration for the company; it has pursued collaborations with external research institutions and dental & medical schools.Through its internal research centers and research collaborations, the company directly invests in developing products and improving its existing offerings.Envista Holdings:Envista focuses on developments in emerging markets.
According to research report Wearable Healthcare Devices Market size is projected to reach USD 46.6 billion by 2025 from USD 18.4 billion in 2020, at a CAGR of 20.5% from 2020 to 2025.Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=81753973Based on applications, the wearable healthcare devices market is segmented into general health and fitness, remote patient monitoring, and home healthcare applications.In 2019, the general health and fitness segment accounted for the largest share of the market, primarily due to the increasing focus on physical fitness among people to improve their quality of life, coupled with the growing trend of tracking health progress on a continuous basis.Based on device type, the wearable medical devices market is segmented into diagnostic & monitoring devices and therapeutic devices.In 2019, the diagnostic & monitoring devices segment accounted for a larger share of 64.3% of the wearable medical devices market.The large share of this segment can be attributed to factors such as the growing prevalence of chronic & lifestyle diseases, the availability of technologically advanced and compact products that can be easily worn, the ability of diagnostic & monitoring devices to diagnose multiple health conditions at relatively earlier stages, and the increasing accuracy of the products.Based on the distribution channel, the wearable medical devices market is segmented into pharmacies, online channels, and hypermarkets.Pharmacies accounted for the largest share of 46.7% of the global wearable medical devices market in 2019.The increasing trend of self-monitoring and non-invasive monitoring and diagnosis has resulted in a substantial increase in the supply of wearable devices in pharmacies.Emerging economies such as China, India and Brazil are expected to provide a wide range of opportunities for players in the market.
According to the new market research report "Digital PCR and qPCR Market by Product (Instruments, Reagents & Consumables, Software & Services), Application (Clinical, Research, Forensic), End User (Hospitals & Diagnostic Centers, Pharma Biotech, CROs) - Global Forecast to 2025", published by MarketsandMarkets™, the dPCR and qPCR market is projected to reach USD 7.6 billion by 2025 from USD 4.9 billion in 2020, at a CAGR of 9.0% between 2020 and 2025.Browse in-depth TOC on "Digital PCR (dPCR) and Real-time PCR (qPCR) Market"253 – Tables41 – Figures316 – PagesDownload PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=174151204 The Factors such as the rising incidence of target infectious diseases and genetic disorders; technological advancements in PCR technologies; increasing investments, funds, and grants; increasing use of biomarker profiling for disease diagnostics; and successful completion of the Human Genome Project are driving the growth of this market.The qPCR reagents and consumables segment is expected to command the largest share of the qPCR products & services market in 2020, owing to the factors such as the expanding applications of qPCR (owing to its technological benefits over traditional PCR, such as real-time analysis and reduced analysis time), growing private-public funding for life science research, and the rising number of probe-based multiplex genetic analysis procedures (that require the analysis of low-volume gene samples).Clinical application segment accounted for the largest share of qPCR marketBased on application, the market is categorized into clinical applications (Infectious Disease Testing, Oncology Testing, Blood Screening, Transplant Diagnostics and Other Clinical Applications), research applications and forensic applications.The key factors driving the market growth of cclinical applications segment include the growing usage of qPCR in disease diagnosis, rising incidence of infectious and genetic diseases, and growing public emphasis on early & effective disease diagnosis & treatment.The hospitals and diagnostic centers is the largest and fastest gowing end user segment of the qPCR marketBased on end users, the dPCR market is segmented into research laboratories and academic institutes, pharmaceutical and biotechnology companies, hospitals and diagnostic centers, clinical research organizations (CROs), and forensic laboratories.This can be attributed to the increasing market availability of qPCR reagents for clinical diagnostic applications, ongoing expansion of healthcare infrastructure across emerging countries, high prevalence of target diseases, and growing awareness among end users related to the benefits offered by qPCR for clinical diagnosis.North America accounted for the largest share of the dPCR marketNorth America accounted for the largest share of the dPCR and qPCR market, followed by Europe in 2019.The large share of the North American regional segment can be attributed to the increased adoption of innovative and novel genomic analysis products (including advanced qPCR and dPCR products), availability of R funding for genomic research (coupled with the robust research infrastructure in the region), expanding use of PCR techniques in clinical diagnostics & forensics, and early commercialization of qPCR/dPCR products compared to other regions.Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=174151204 The prominent players operating in the dPCR and qPCR market are Thermo Fisher Scientific (US), Bio-Rad Laboratories Inc. (US), and F. Hoffmann-La Roche, Ltd. (Switzerland).About MarketsandMarkets™MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies' revenues.Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients.
According to research report the cardiac monitoring devices market is projected to reach USD 25.0 billion by 2024 from USD 20.7 billion in 2019, at a CAGR of 3.9%.Growth in this market is primarily driven by the increasing incidence of cardiovascular diseases; technological advancements; increasing investments, funds, and grants for research on CM & CRM devices; and the growing preference for wearable cardiac devices.Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=55The major players in the cardiac monitoring devices market include Medtronic (Ireland), Boston Scientific (US), Abbott Laboratories (US), GE Healthcare (US), BIOTRONIK (Germany), Koninklijke Philips (Netherlands), and Hill-Rom Holdings (US).Various growth strategies have been adopted by these players, such as product launches, contracts, agreements, collaborations, partnerships, and acquisitions to increase their presence in the global cardiac monitoring devices market.Abbott Laboratories (US)Abbott has a strong foothold in the cardiac monitoring devices market.In 2017, Abbott entered the pacemakers market with the acquisition of St. Jude Medical (US).Abbott received approval for its magnetic resonance (MR)-conditional labeling for both the Assurity MRI pacemaker and the Tendril MRI pacing lead.The Assurity MRI pacemaker is the worlds smallest and longest-lasting wireless MRI-compatible pacemaker, which gives added advantage to the company, thus helping the firm in maintaining its position as the market leader.Request For Report Sample: https://www.marketsandmarkets.com/requestsampleNew.asp?id=55Medtronic (Ireland)Medtronic is one of the leading companies in the cardiac monitoring devices market.In order to maintain its position, Medtronic continuously launches advanced products in this market.
According to the new market research report "In Vitro Diagnostics Quality Control Market by Source (Plasma, Whole Blood, Urine), Technology (Immunoassay, Hematology, Microbiology, Molecular Diagnostics), Manufacturer (Third-party, OEM), End Users (Hospitals, Lab) - Global Forecast to 2026", published by MarketsandMarkets™, the global IVD Quality Control Market is projected to reach USD 1.4 billion by 2026 from USD 1.1 billion in 2021, at a CAGR of 5.3% during the forecast period.Browse in-depth TOC on "In Vitro Diagnostics Quality Control Market"252 – Tables59 – Figures342 – PagesDownload PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=198032582 The IVD testing plays a significant role in clinical decision-making.To ensure technological competitiveness, companies are continuously launching innovative and advanced quality control products in the market for a variety of applications.The growth of the Quality Control in IVD Market is primarily driven by the rising number of accredited clinical laboratories, rising geriatric population, rising demand for external quality assessment programs, increasing adoption of and POC instruments in developed regions and increasing adoption of third-party quality controls.The rising focus on multi-analyte controls is also expected to offer significant growth opportunities for the market in the coming years.The lack of regulations for these products is expected to adversely affect market growth.The product & service segment holds the highest share of the total IVD quality control market during the forecast period.Based on product & service, the IVD Quality Control Market is segmented into quality control products, data management solutions, and quality assurance services.The large share of this segment can be attributed to the increasing use of third-party quality controls across the globe to verify the accuracy and reliability of testsHospitals accounted for the highest share of the global IVD quality control marketThe key end users of IVD quality controls studied in this report include hospitals, clinical laboratories, research & academic institutes, and other end users.Recommendations for and approvals of quality control products from the FDA and the College of American Pathologists (CAP) and the presence of well-established distribution channels and leading companies in the US are driving the market in North America.Request For Report Sample: https://www.marketsandmarkets.com/requestsampleNew.asp?id=198032582 Some of the key players in the In Vitro Diagnostics (IVD) Quality Control Market include Bio-Rad Laboratories, Inc. (US), Randox Laboratories Ltd. (UK), Thermo Fisher Scientific, Inc. (US), LGC Limited (UK), and Abbott Laboratories (US).
According to the new market research report “Immunoassay Market by Product (Reagents & Kits, Analyzers), Technology (ELISA, IFA, Rapid Tests, Radio Immunoassay), Specimen (Blood, Saliva, Urine), Application (Infectious Diseases, Oncology), End User (Hospitals & Clinics) – Global Forecast to 2026”, published by MarketsandMarkets™, the global Immunoassay Market is projected to reach USD 39.0 billion by 2026 from USD 28.4 billion in 2021, at a CAGR of 6.6% during the forecast period.Browse in-depth TOC on “Immunoassay Market” 334 – Tables 55 – Figures 395 – PagesDownload PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=436 The surging incidence of chronic and infectious diseases, technological advancements of immunoassay products, and their massive adoptions are the major factors driving the growth of the market.In 2020, reagents & kits accounted for the largest share of the market and is also expected to grow at the highest CAGR during the forecast period.Based on the product, the immunoassay market is segmented into reagents & kits and analyzers.The large share of this segment can be attributed the massive consumption of ELISA in the diagnosis of cancer, infectious diseases, and other chronic complications.Blood account for the largest share and are expected to grow at the highest CAGR during the forecast period.Based on the specimen, the immunoassay market is segmented into blood, saliva, urine and other specimens.In addition, hospitals & clinics work as reference laboratories to small hospitals and physician offices.North America was the largest regional market for the market in 2020The immunoassay market is segmented into four major regions, namely, North America, Europe, Asia Pacific, Latin America and the Middle East & Africa.Emerging APAC economies such as China, India and South Korea are expected to see significant growth due to their expanding geriatric population, rising prevalence of chronic diseases, improving healthcare technology and the increasing disposable income.The global immunoassay market is consolidated.The prominent players operating in this market include Danaher (US), Thermo Fisher Scientific (US), Abbott Laboratories (US) and Roche (Switzerland).About MarketsandMarkets™MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies' revenues.Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients.
According to the new market research report “Single-use Bioreactors Market by Product (System, 2D, 3D Media Bag, Filtration Assemblies), Molecule (mAbs, Vaccine), Cell type (Mammalian, Bacteria), Application (R, Process Development), End User (Biopharma, CROs & CMOs) – Global Forecast to 2026”, published by MarketsandMarkets™, the global Single-Use Bioreactors Market is projected to reach USD 8.8 billion by 2026 from USD 3.4 billion in 2021, at a CAGR of 21.1% during the forecast period.Browse in-depth TOC on “Single-use Bioreactors Market”235 – Tables32 – Figures207 – PagesDownload PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=49113750 Increasing adoption of SUBs among small companies and startups, reduced automation complexity, ease in the cultivation of marine organisms, reduced energy and water consumption, the growing biologics market, technological advancements in SUBs, and increasing Biopharmaceutical R are factors driving the growth of this market.Single-use bioreactor systems accounted for the largest share of single-use bioreactors marketBased on product, the single-use bioreactors market is categorized into single-use bioreactor systems, single-use media bags, single-use filtration assemblies, and other products such as single-use vessels, tubing, connectors, control systems, and probes/sensors, among others.SUB systems offer benefits such as lower capital investment, lower operating expenses, and lower environmental footprint, thus driving the growing adoption of these systems in biopharma applications.Stirred-tank SUBs accounted for the largest share of single-use bioreactors marketBased on type, the single-use bioreactors market is categorized into wave-induced SUBs, stirred-tank SUBs, bubble-column SUBs, and other bioreactors such as hybrid bioreactors and SUBs with vertically perforated discs.The stirred-tank SUBs are highly preferred in the cultivation of aerobic microbial cultures as it promote greater oxygen transfer and reduced engineering challenges such as heat removal, mass transfer, and higher agitation rates.The contract research organizations (CROs) and contract manufacturing organizations (CMOs) is the fastest-growing end user segment of the single-use bioreactors marketBased on end users, the single-use bioreactors market is segmented into pharmaceutical & biopharmaceutical companies, contract research organizations and contract manufacturing organizations (CROs and CMOs), and academic & research institutes.The increasing outsourcing of R and manufacturing services by pharmaceutical and biopharmaceutical companies is expected to support the growth of the CROs & CMOs segment.North America accounted for the largest share of the single-use bioreactors marketNorth America accounted for the largest share of the single-use bioreactors market, followed by Europe in 2020.The large share of the North American regional segment can be attributed to the presence of a well-established biopharmaceutical industry and major players operating in the single-use bioreactors market.Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=49113750 The prominent players operating in the single-use bioreactors market are Sartorius Stedim Biotech (France), Thermo Fisher Scientific (US), Danaher Corporation (US), and Merck KGaA (Germany).About MarketsandMarkets™MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies' revenues.Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients.
According to the new market research report "eHealth Market by Solutions (EMR, PACS & VNA, RIS, LIS, CVIS, Telehealth, eRx, HIE, Patient Portal, Medical Apps), Services (Remote Patient Monitoring, Diagnostic Services) End User - Global Forecast to 2025", published by MarketsandMarkets™, the eHealth Solutions Market is projected to reach USD 193.8 billion by 2025 from USD 69.5 billion in 2020, at a CAGR of 22.8% during the forecast period.Browse in-depth TOC on "eHealth Market"181 – Tables38 – Figures270 – PagesDownload PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=11513143 Factors such as the increased adoption eHealth solutions, rising elderly population base, and the growing number of infectious diseases are expected to drive the growth of the market.By-eHealth solutions, the EMR/EHR is expected to dominate the eHealth market in 2020Based on eHealth solutions, the eHealth solutions market has been segmented into EHR/EMR Solutions, Medical Apps, Picture Archiving and Communication Systems & Vendor Neutral Archive, Chronic Care Management Apps, PHR & Patient Portals, Health Information Exchange Solutions, Telehealth Solutions, Pharmacy Information Systems, Laboratory Information Systems, Clinical Decision Support Systems, E-Prescribing Solutions, Radiology Information Systems, Cardiovascular Information Systems, Other Specialty Information Systems.Within eHealth solutions market, EMR/EHR accounted for the largest share in 2020.Recently developed telehealth solutions are exceptionally superior and speed up patient recovery.Thus, above mentioned factors are expected to drive the segmental growth.North America holds the largest share in the market in 2020, followed by EuropeNorth America dominates the overall market based on region.Furthermore, the regulatory scenario is quite stringent in the region that ensures the availability of defect-free eHealth solutions in the market that proves beneficial for market growth.Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=11513143 The players in the eHealth market include Allscripts (US), athenahealth (US), Epic Systems (US), IBM (US), GE Healthcare (US), Cerner (US), Optum (US), Philips Healthcare (Netherlands), Siemens Healthineers (Germany), McKesson (US), Medtronic (Ireland), and Cisco Systems (US)About MarketsandMarkets™MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies' revenues.Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients.
More

Top